As interest in GLP-1 treatments like Ozempic grows, employees are increasingly inquiring about coverage for weight loss, prompting HR departments to develop strategies that address both financial viability and the long-term impact of these medications. Click here for article.
Employee Interest in Coverage: The rise in inquiries about GLP-1 coverage highlights a demand for weight loss treatments beyond diabetes management, necessitating HR planning.
Financial Considerations: Experts emphasize the need for employers to evaluate the costs associated with obesity-related conditions and ensure coverage aligns with pharmacy benefit management to avoid future discrepancies.
Maximizing ROI Through Feedback: HR leaders are encouraged to conduct employee surveys to understand needs related to GLP-1 treatments, integrating patient engagement and supportive programs for better outcomes.
Long-Term Impact Assessment: Employers should consider the sustained effectiveness of GLP-1 treatments, understanding that significant weight loss and ongoing support are crucial for achieving a positive return on investment.
Comments